Sort
10,766 grants matching “checkpoint inhibitor”
Targeting Wnt signaling in therapy-resistant ovarian cancer
$333,493Benjamin G Bitler · University Of Colorado Denver · R37 · FY2024 · CA
Manipulation of Tumor Specific Immunity
$333,450Hans Schreiber · University Of Chicago · R01 · FY2023 · CA
Manipulation of Tumor Specific Immunity
$333,450Hans Schreiber · University Of Chicago · R01 · FY2021 · CA
Hec1 network as molecular therapeutic targets
$333,338University Of California Irvine · R01 · FY2004 · CA
ATM as target for malignant glioma radiosensitization.
$333,230Kristoffer Valerie · Virginia Commonwealth University · R01 · FY2013 · NS
Project 4
$333,121Paulo Cesar Rodriguez · H. Lee Moffitt Cancer Ctr & Res Inst · P01 · FY2022 · CA
PTP1b Inhibition Restores the Innate Anti-tumor Response During Chemotherapy
$333,073Eric S Ubil · University Of Kentucky · R01 · FY2025 · CA
A Novel Carcinogen-Induced Cell Cycle Checkpoint
$333,000Cyrus Vaziri · Univ Of North Carolina Chapel Hill · R01 · FY2016 · ES
Project 1: Personalized Adjuvant Immunotherapy for High-risk Colorectal Cancer.
$332,973Michael J Overman · University Of Tx Md Anderson Can Ctr · P50 · FY2023 · CA
A prognostic mRNA immune signature for resected stage II-III melanoma
$332,806Yvonne Margaret Saenger · Albert Einstein College Of Medicine · UH3 · FY2023 · CA
Improvement of cellular immunotherapy during dysbiosis- Resubmission
$332,749Ruud P.m. Dings · Univ Of Arkansas For Med Scis · R01 · FY2024 · CA
Targeting Chronic ER Stress in T Cells to Improve Cancer Immunotherapy
$332,665Jessica E Thaxton · Univ Of North Carolina Chapel Hill · R01 · FY2024 · CA
The Role of BRCA1/BARD1 in Basal-like Breast Cancer
$332,623Richard J Baer · Columbia University Health Sciences · R01 · FY2009 · CA
Project 1: Remodeling Chromatin and the Tumor Microenvironment: Direct Oncogenesis and Therapeutic Targeting
$332,593David E Fisher · Massachusetts General Hospital · P01 · FY2022 · CA
Project 3: Maximizing Anti-tumor Activity through Simultaneous Activation of the Innate and Adaptive Immune System in Kidney Cancer
$332,494Raquibul Hannan · Ut Southwestern Medical Center · P50 · FY2022 · CA
Control of Microtubule and Genome Integrity by the OBSL1-CUL7-CUL9-p53 Pathway
$332,383Yue Xiong · Univ Of North Carolina Chapel Hill · R01 · FY2016 · CA
Control of Microtubule and Genome Integrity by the OBSL1-CUL7-CUL9-p53 Pathway
$332,383Yue Xiong · Univ Of North Carolina Chapel Hill · R01 · FY2015 · CA
Control of Microtubule and Genome Integrity by the OBSL1-CUL7-CUL9-p53 Pathway
$332,383Yue Xiong · Univ Of North Carolina Chapel Hill · R01 · FY2012 · CA
Cyclin-Dependent Kinase Inhibition During S Phase
$332,325Geoffrey I Shapiro · Dana-Farber Cancer Inst · R01 · FY2010 · CA
Project 4-Modulating Innate Immunity to Overcome Resistance to PD-1/PD-L1 Blockade
$332,308Harriet M Kluger · Yale University · P50 · FY2021 · CA
Project 4-Modulating Innate Immunity to Overcome Resistance to PD-1/PD-L1 Blockade
$332,297Harriet M Kluger · Yale University · P50 · FY2019 · CA
Development of novel metastatic mouse models that recapitulate the major immune contexts of human colon cancer
$332,226Tyler E Jacks · Massachusetts Institute Of Technology · R01 · FY2020 · CA
Pathways of Immune Evasion in Acute Myeloid Leukemia
$332,159Evan Ferguson Lind · Oregon Health & Science University · R01 · FY2024 · CA
Core B: Biospecimen Repository and Processing Core
$332,084Begonya Comin-Anduix · University Of California Los Angeles · P01 · FY2024 · CA
Targeting Endoplasmic Reticulum Stress Sensor IRE1 to Enhance Chemotherapy Sensitivity in MYC-driven breast cancer
$332,039Xi Chen · Baylor College Of Medicine · P50 · FY2023 · CA